Plain-English translation of NCT07279077 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment for advanced colon cancer using three therapies together: low-dose radiation therapy, chemotherapy (CAPOX), and a PD-1 inhibitor — a medication that helps your immune system fight cancer cells. The study focuses on colon cancers that don't respond well to immune therapy alone, and the researchers believe that adding low-dose radiation might make the immune medication work better.
Most advanced colon cancers don't respond well to immune-boosting treatments on their own. Recent research suggests that low-dose radiation can 'wake up' the immune system and make it better able to recognize and attack cancer cells, so combining it with chemotherapy and this medication might help more patients achieve better outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive four 3-week cycles of treatment combining low-dose radiation (given twice at the start), chemotherapy, and the PD-1 inhibitor medication. During this time, you'll have regular clinic visits for blood tests, imaging scans, and clinical exams to monitor how you're responding. After completing this neoadjuvant (pre-surgery) treatment, you would undergo surgery to remove the cancer, followed by standard follow-up care.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China